Osaka City General Hospital
Osaka City General Hospital
Osaka, Osaka, Japan6 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) | Epilepsies, Myoclonic, Epilepsy, Generalized, Epileptic Syndromes, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, brain disorder, central nervous system disorder, epilepsy, nervous system disorder, neurodevelopmental disorder, psychiatric disorder, visual epilepsy | Active, not recruiting | Phase 3 | 2026-09-17 | NCT06660394 | |
| A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Epilepsies, Myoclonic, Epilepsy, Generalized, Epileptic Syndromes, Lennox-Gastaut syndrome, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, brain disorder, central nervous system disorder, developmental and epileptic encephalopathy, epilepsy, hereditary disease, nervous system disorder, neurodevelopmental disorder, psychiatric disorder, visual epilepsy | Enrolling by invitation | Phase 3 | 2026-09-15 | NCT06908226 | |
| A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Epileptic Syndromes, Lennox-Gastaut syndrome, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, brain disorder, central nervous system disorder, developmental and epileptic encephalopathy, epilepsy, hereditary disease, nervous system disorder, neurodevelopmental disorder, psychiatric disorder, visual epilepsy | Active, not recruiting | Phase 3 | 2026-09-15 | NCT06719141 | |
| A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung cancer, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 3 | 2026-08-26 | NCT07128199 | |
| REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 3 | 2026-07-30 | NCT05973773 | |
| Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial | Arterial Occlusive Diseases, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, vascular disorder | Active, not recruiting | Phase 3 | 2026-02-27 | NCT05581303 |